Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Novosti v dopolnilnem zdravljenju HER2-pozitivnega raka dojke
Authors:Matos, Erika (Author)
Language:Slovenian
Tipology:1.04 - Professional Article
Organisation:Logo OI - Institute of Oncology
Year of publishing:2008
COBISS_ID:620411 Link is opened in a new window
UDC:616-006
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
URN:URN:NBN:SI:doc-BRZ6IBU5
Views:1513
Downloads:331
Files:.pdf PDF - Presentation file, download (377,95 KB)
 
Journal:Onkologija
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Update on Adjuvant Treatment of HER2-Positive Breast Cancer
Abstract:Although trastuzumab-based regimens have improved both systemic control and overall survival in the patients with HER2-positive breast cancer, in some of these patients, tumor progression occurs despite trastuzumab treatment. New target therapies are searched for these patients. The most promising and, in terms of clinical use, the most developed is lapatinib, a small molecule, tyrosine-kinase inhibitor that targets not only HER2- but also HER1-receptor. It is already used for treating the HER2-positive metastatic breast cancer patients after failure of trastuzumab therapy, but its effectiveness in adjuvant therapy has not been proven yet. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) is a randomized phase-three multi-center study of adjuvant lapatinib, trastuzumab, their sequence and their combination in the patients with HER2 positive primary breast cancer.

Archive

niGradiv

Back